Question · Q3 2025
Ryan McDowell asked about the primary drivers behind Tempus AI's robust genomics volume growth, seeking to understand if it's largely due to broader industry shifts towards NGS testing or specific Tempus-controlled factors like sales force optimization and integrated technology.
Answer
CEO Eric Lefkofsky attributed the strong performance mainly to Tempus AI's more efficient sales force, which has overcome previous disruptions, and the company's integrated technology that delivers comprehensive, contextualized results. He acknowledged general market tailwinds from increased biomarker identification but clarified that Tempus AI's growth is not reliant on one-time benefits from concurrent or sequential testing shifts, given their long-standing comprehensive portfolio.
Ask follow-up questions
Fintool can predict
TEM's earnings beat/miss a week before the call